Proton pump inhibitors - a sting in the tale? by Cheung, BMY et al.
VOL.15  NO.12  DECEMBER  2010
OFFICIAL PUBLICATION FOR THE FEDERATION OF MEDICAL SOCIETIES OF HONG KONG    ISSN 1812 - 1691
Gastroenterology and               
Hepatology

VOL.15  NO.12  DECEMBER  2010
    1
Contents
  Editorial
n Editorial 
Dr. Chi-kuen CHAN
2
  Medical Bulletin
n Proton Pump Inhibitors – a Sting in the Tale?
Prof. Bernard M.Y. CHEUNG
Dr. Ivan FN HUNG
Dr. SY WONG  
4
n MCHK CME Programme Self-assessment Questions 6
n Update on Management of Helicobacter 
Pylori Infection
Dr. Benjamin CY WONG
8
n Updates in the Treatment of Chronic Hepatitis C
Dr. James FUNG
Dr. Ching-lung LAI 
Dr. Man-fung YUEN
12
n Recent Advances in Management of 
Hepatocellular Carcinoma
Prof. Ronnie Tung-ping POON 
18
n Voluntary Health Protection Scheme: the right choice 
for the next step of Hong Kong’s healthcare reform? 
Prof. Geoffrey LIEU
24
Dermatological Quiz
n Dermatological Quiz
Dr. Lai-yin CHONG  
28
Society News 31
Medical Diary of December 29
Calendar of Events
n Courses / Meeting 31
Contents
The Cover Shot
Disclaimer 
All materials published in the Hong Kong Medical Diary represent the opinions of the authors responsible for the articles and do not 
reflect the official views or policy of the Federation of Medical Societies of Hong Kong, member societies or the publisher. 
Publication of an advertisement in the Hong Kong Medical Diary does not constitute endorsement or approval of the product or 
service promoted or of any claims made by the advertisers with respect to such products or services. 
The Federation of Medical Societies of Hong Kong and the Hong Kong Medical Diary assume no responsibility for any injury and/or 
damage to persons or property arising from any use of execution of any methods, treatments, therapy, operations, instructions, ideas 
contained in the printed articles. Because of rapid advances in medicine, independent verification of diagnoses, treatment method and 
drug dosage should be made. 
The Lone Faithful
The solitary worshipper walks in quiet solitude across the 
grand halls of Istanbul’s St Sophia Cathedral, now a mosque. 
As he hold a steady pace, he is praying to god. 
The many candlelights highlight the grandeur of this house of 
worship. 
f8, 1/50sec, ISO 800, at 55mm
Dr. Amy LM PANG
MBBS(HK), 
FRCR, FHKCR, 
FHKAM(Radiology)
Specialist in Radiology 
CME
VOL.15  NO.12  DECEMBER  2010
    2
Editorial
Published by 
The Federation of Medical Societies of Hong Kong
EDITOR-IN-CHIEF
Dr. MOK Chun-on
莫鎮安醫生    
EDITORS
Prof. CHAN Chi-fung, Godfrey
陳志峰醫生   (Paediatrics)
Dr. CHAN Chun-hon, Edmond
陳振漢醫生   (General Practice)
Dr. KING Wing-keung, Walter
金永強醫生  (Plastic Surgery)
EDITORIAL BOARD
Dr. CHAN Chi-kuen
陳志權醫生 (Gastroenterology & Hepatology) 
Dr. CHAN Chi-wai, Angus
陳志偉醫生   (General Surgery)
Dr. CHAN Chun-kwong, Jane
陳真光醫生 (Respiratory Medicine)
Dr. CHAN Hau-ngai, Kingsley
陳厚毅醫生   (Dermatology & Venereology)
Dr. CHAN, Norman
陳諾醫生   (Diabetes, Endocrinology & Metabolism)
Dr. CHIANG Chung-seung
蔣忠想醫生   (Cardiology)
Dr. CHIM Chor-sang, James
詹楚生醫生   (Haematology)
Dr. CHONG Lai-yin
莊禮賢醫生   (Dermatology & Venereology)
Dr. FAN Yiu-wah
范耀華醫生   (Neurosurgery)
Dr. FONG To-sang, Dawson 
方道生醫生  (Neurosurgery) 
Prof. HO Pak-leung
何栢良醫生   (Microbiology)
Dr. KWOK Po-yin, Samuel
郭寶賢醫生   (General Surgery)
Dr. LAI Sik-to, Thomas
黎錫滔醫生   (Gastroenterology & Hepatology)
Dr. LAI Yuk-yau, Timothy
賴旭佑醫生   (Ophthalmology)
Dr. LAM Tat-chung, Paul
林達聰醫生   (Psychiatry)
Dr. LAM Wai-man, Wendy
林慧文醫生   (Radiology)
Dr. LEE Kin-man, Philip
李健民醫生  (Oral & Maxillofacial Surgery) 
Dr. LEE Man-piu, Albert
李文彪醫生   (Dentistry)
Dr. LEUNG Kwok-yin 
梁國賢醫生  (Obstetrics & Gynaecology) 
Dr. LO See-kit, Raymond
勞思傑醫生   (Geriatric Medicine)
Dr. MAN Chi-wai
文志衛醫生   (Urology)
Dr. MOK, Mo-yin
莫慕賢醫生   (Rheumatology)
Dr. SIU Wing-tai 
蕭永泰醫生 (General Surgery)
Dr. TSANG Wai-kay
曾偉基醫生   (Nephrology)
Prof. WEI I, William
韋霖醫生   (Otorhinolaryngology)
Dr. WONG Bun-lap, Bernard
黃品立醫生   (Cardiology)
Dr. YU Chau-leung, Edwin
余秋良醫生  (Paediatrics) 
Design and Production
Dr. Chi-kuen CHAN
Editorial
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In this issue, we have picked some hot topics in gastroenterology and 
hepatology for review. Dr. Benjamin CY Wong wrote on the update 
in H. pylori infection and the available options when resistance 
was encountered. Dr. James YY Fung took a review on the current 
management of chronic HCV infection, and the new therapeutics for 
non-responders. Prof. Bernard MY Cheung summarised the current 
indications and concerns regarding proton pump inhibitors. Prof 
TP Poon highlighted the various treatment modalities on inoperable 
hepatocellular carcinoma.
Common GI symptoms and diseases could be managed in the 
primary care setting.  We need to apply evidence based medicine to 
patient care. Judicious use of clinical care research results is important 
in the management of individual patients.
In this issue there is an invited article by Prof. Geoffrey Lieu on the 
Healthcare Reform Second Stage Public Consultation. A voluntary 
and Government-regulated Health Protection Scheme (HPS) is 
proposed. The HPS aims to provide more choices with better 
protection in private health insurance and private healthcare services. 
The deadline of the consultation is 7 Jan. 2011. Your views may be 
given to these contacts: Email: mychoice@fhb.gov.hk and Website: 
www.MyHealthMyChoice.gov.hk.
MBBS (HK), FHKAM (Medicine)
Specialist in Gastroenterology and Hepatology
Editor
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Why then, can one desire too much of a good thing?
William Shakespeare, ‘As You Like It’ 
The proton pump inhibitors (PPIs) are potent inhibitors 
of gastric acid production. Omeprazole was the 
first PPI introduced.  Subsequently, lansoprazole, 
pantoprazole, rabeprazole and the S-enantiomer of 
omeprazole became available. As they suppress acid 
more efficaciously than H2-receptor antagonists, they 
are now widely used for the treatment of conditions 
such as peptic ulcer disease,1, 2 gastro-oesophageal reflux 
disease (GERD),3 nonsteroidal anti-inflammatory drug 
(NSAID)-induced gastrointestinal lesions,4, 5 Zollinger-
Ellison syndrome, dyspepsia and, together with two 
antibiotics, eradication of Helicobacter pylori infection.6
PPIs are more expensive than H2-receptor antagonists; 
the current difference in price is about 10-fold. 
Therefore, cost-effectiveness could be an issue.  While 
PPIs are superior to H2-receptor antagonists in the 
resolution of symptoms and healing of ulceration,3 there 
are not much significant differences among different 
PPIs.7, 8  In high risk patients with peptic disease, e.g. 
a patient with fresh melaena,  PPI given intravenously 
has been shown to be effective in downstaging 
the endoscopic lesion and decreasing the need for 
endoscopic intervention.2  Intravenous PPI reduces 
rebleeding and mortality after endoscopic treatment.9 
Complicated peptic diseases should also be treated 
with a course of PPI for 6-8 weeks.  In uncomplicated 
helicobacter-negative peptic disease, an H2-receptor 
antagonist may suffice, with PPI as second line 
treatment if the ulcer fails to heal after 8 weeks.  PPI is 
also used for the prevention of gastrointestinal bleeding 
in patients on long term NSAIDs and aspirin (table 1).4, 5
In general, PPIs are very well tolerated.  Side-effects 
are uncommon and usually minor.  However, there 
are recent concerns about osteoporotic fractures, 
susceptibility to infections and interaction with 
clopidogrel diminishing its antiplatelet effect.
The suppression of gastric acid by a PPI can be up 
to 99%.  While this facilitates the healing of ulcers 
and reduces the pain due to acid in the stomach or 
oesophagus, the lack of gastric acid, hypochlorhydria, 
may affect the digestion of proteins and the absorption 
of vitamin B12 and calcium.  It is also thought that 
insufficient acid may lead to bacterial overgrowth 
and increase the risk of pneumonia.10 Therefore, it has 
been suggested that patients at high risk of pneumonia 
should be prescribed PPI only when necessary and at a 
lower dose.11  Similarly, prolonged treatment with a PPI 
may increase the risk of Clostridium difficile infection 
substantially.12  
Table 1A.  Patients at increased risk of gastrointestinal 
toxicity due to NSAID
High risk
1. History of a previously complicated ulcer, especially recent
2. Multiple (>2) risk factors
Moderate risk (1-2 risk factors)
1. Age >65 years
2. High dose NSAID therapy
3. A previous history of uncomplicated ulcer
4. Concurrent use of aspirin (including low dose), corticosteroids 
    or anticoagulants
Low risk
1.No risk factors
   H. Pylori is an independent and additive risk factor and should 
   be addressed separately. 
Table 1B.  Summary of recommendations for prevention of 
NSAID-related ulcer complications
Gastrointestinal risk
Low Moderate High
Low cardio-
vascular risk
NSAID alone 
(the least 
ulcerogenic 
NSAID at the 
lowest effective 
dose)
NSAID + PPI/
misoprostol
Alternative 
therapy if 
possible 
or COX-2 
inhibitor + PPI/
misoprostol
High cardio-
vascular 
risk (low-
dose aspirin 
required)
Naproxen + PPI/
misoprostol
Naproxen + PPI/
misoprostol
Avoid NSAIDs 
or COX-2 
inhibitors. Use  
alternative 
therapy
Adapted from American College of Gastroenterology Guidelines for 
prevention of NSAID-related ulcer complications5  
There are also concerns that prolonged use of PPIs 
might cause osteoporosis and increase the risk of 
fractures of the hip, wrist, and spine.  In a study of 
135,000 people aged 50 or above, those taking high doses 
of PPI for longer than a year were 2.6 times more likely 
to have sustained a hip fracture.13  The risk of a fracture 
increases with dose and duration.  The precise reasons 
for this are unclear, but it is thought that a rise in pH 
may reduce the solubility of calcium and consequently 
its absorption.  The Food and Drugs Administration 
of the United States has requested a change in the 
drug labelling to include the possible increased risk of 
fractures.14
This article has been selected by the Editorial Board of the Hong Kong Medical Diary for participants in the CME programme of the Medical 
Council of Hong Kong (MCHK) to complete the following self-assessment questions in order to be awarded one CME credit under the programme 
upon returning the completed answer sheet to the Federation Secretariat on or before 31 December 2010.
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The interaction of PPI with clopidogrel has come under 
the spotlight recently. Clopidogrel is an antiplatelet 
agent that has a marginally superior cardiovascular 
outcome and better gastrointestinal side-effect profile 
compared to aspirin.15 It is used together with aspirin 
in acute coronary syndrome and after percutaneous 
coronary intervention.  Clopidogrel is inactive and 
requires metabolism by cytochrome P450 enzymes to 
achieve its therapeutic effect.  People with a variant in 
CYP2C19 metabolise clopidogrel poorly and therefore 
the antiplatelet effect is diminished.16  In Hong Kong, 
about 18% of the population are poor metabolisers 
in this respect.17  Patients on long term clopidogrel, 
especially those also taking aspirin, may require an 
acid suppressing agent.  In this situation, a PPI could 
be hazardous as it might block the metabolism of 
clopidogrel into its active form.18  This can lead to an 
increase in the risk of myocardial infarction.19  Whereas 
similar findings were observed only in retrospective 
studies, other post hoc analyses, prospective studies and 
a randomised controlled trial revealed no increase in 
major cardiac events related to cotherapy.20 In the face 
of conflicting evidence, the current recommendation 
is not to use PPI in a patient on clopidogrel unless 
it is essential to do so.21, 22 If PPI is indicated, then a 
PPI with a lower likelihood of interaction should be 
considered, as the potential for interactions among 
these agents varies. Omeprazole and esomeprazole are 
metabolised mainly via CYP2C19 and therefore have the 
highest potential for interaction.23 Rabeprazole is also 
metabolised via this isoenzyme, but posesses significant 
affinity for CYP3A4 resulting in fewer clinically 
significant interactions. Pantoprazole, on the other hand, 
is primarily metabolised via CYP2C19 O-demethylation 
rapidly followed by sulfate conjugation. As a result, 
pantoprazole has the lowest potential for P450 
metabolism and drug-drug interaction and should 
be the preferred PPI for patients on clopidogrel. 
Ticargrelor and prasugel,24 two new antiplatelet drugs, 
do not require metabolism to be active and may have 
an advantage over clopidogrel if they are proven to be 
clinically as effective.
Like all drugs classified as poisons, PPIs carry risks as 
well as benefits.  In the United States, they are the third 
best-selling class of drugs, suggesting a large degree of 
overprescribing.  The appropriate use of PPIs should be 
promoted.  This would include using alternative drugs 
for dyspepsia and uncomplicated peptic ulcer disease, 
and limiting the duration of PPI treatment.
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MCHK CME Programme Self-assessment Questions
ANSWER SHEET FOR DECEMBER 2010
Answers to November 2010 Issue
Please read the article entitled “Proton Pump Inhibitors – A Sting in the Tale?” by Prof. Bernard M.Y. Cheung, 
Dr. Ivan F.N. Hung and Dr. S.Y. Wong and complete the following self-assessment questions. Participants in 
the MCHK CME Programme will be awarded 1 CME credit under the Programme for returning completed 
answer sheets via fax (2865 0345) or by mail to the Federation Secretariat on or before 31 December 2010. 
Answers to questions will be provided in the next issue of The Hong Kong Medical Diary.  
Questions 1-10: Please answer T (true) or F (false) 
Please return the completed answer sheet to the Federation Secretariat on or before 31 December 2010 for 
documentation. 1 CME point will be awarded for answering the MCHK CME programme (for non-specialists) 
self-assessment questions. 
1. Proton pump inhibitors (PPIs) suppress acid more efficaciously than H2-receptor antagonists (H2RAs).
2. PPIs and H2RAs are equally effective in symptom resolution and ulcer healing.
3. Intravenous PPIs or H2RAs have shown to be equally effective in down staging  endoscopic lesions and   
  decreasing the need for endoscopic intervention.
4. PPIs and H2RAs are commonly used for the prevention of GI bleeding in patients on long term NSAIDs and   
 aspirin. They are of similar efficacy.
5. Prolonged treatment with PPIs may increase the risk of C. difficile infection substantially.
6. The risk of pneumonia is not related to the degree of gastric acid suppression.
7. Prolonged use of PPIs might increase the risk of fractures.
8. The risk of fracture increases with dose and duration of PPIs.
9. Concomitant use of an PPI and clopidogrel could be hazardous as PPIs might block the metabolism of    
 clopidogrel into its active form.
10. Pantoprazole has the highest potential for P450 metabolism.
Proton Pump Inhibitors – a Sting in the Tale?
Practical Approach for “Eczema” 
1 4 82 5 93 76 10
1. F F T F F F FT T T4. 8.2. 5. 9.3. 7.6. 10.
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Pylori Infection
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FRCP (Glasgow), FRCP (Edinburgh)
Specialist in Gastroenterology and Hepatology
Honorary Clinical Professor, Department of Medicine, University of Hong Kong
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Introduction
The discovery of Helicobacter pylori led to the award 
of the Nobel Prize to two scientists Dr Robin Warren 
and Dr Barry Marshall in 2005. Although there has 
been intense research on this bacterium which affects 
half of the world’s population, there are still areas of 
controversy and the ideal simple regime of treatment 
is yet to come. This article summarises some of the 
important issues related to indication, diagnosis and 
treatment of H. pylori.
Indications
Three indications for treatment are supported by 
definite evidence with clinical benefits (Table 1). Most 
physicians are aware of these conditions. Patients with 
active or past history of gastric or duodenal ulcers with 
or without ulcer complications (bleeding, perforation, 
gastric outlet obstruction) should be tested for H pylori, 
and if positive, be treated. The treatment not only heals 
the ulcer but will prevent relapse of the ulcer in the long 
run. Patients with gastric MALT lymphoma and those 
with early gastric cancer after endoscopic or surgical 
resection should also be tested and treated if positive.
Table 1.  Indications for treatment
Definite evidence of clinical benefits
1. Active or past history of gastric and/or duodenal ulcers/ erosions, 
with or without complications
2. Gastric mucosa-associated lymphoid tissue (MALT) lymphoma
3. Early gastric cancer after resection
Supportive evidence of clinical benefits
1. Gastric cancer prevention in high risk populations
2. Uninvestigated dyspepsia
3. Functional dyspepsia 
4. Patients’ wishes
5. Family history of gastric cancer
6. Atrophic gastritis
7. Patients on aspirin or non-steroidal anti-inflammatory drugs
8. Patients with GERD requiring long term proton pump inhibitors
9. Other intestinal and extra-intestinal diseases: unexplained iron 
deficiency anaemia, idiopathic thrombocytopenic purpura, 
lymphocytic gastritis, gastric hyperplastic polyps, Menetrier’s 
disease
Other indications for treatment have supportive 
evidence of clinical benefits (Table 1). These include (1) 
early gastric cancer after resection, (2) gastric cancer 
prevention in high risk populations, (3) uninvestigated 
dyspepsia, (4) functional dyspepsia, (5) patients’ wishes, 
(6) first degree relatives with gastric cancer, (7) patients 
on aspirin or non-steroidal anti-inflammatory drugs. 
Other indications are not so well supported, including 
patients with atrophic gastritis or intestinal metaplasia, 
patients with gastro-oesophageal reflux disease 
requiring long term proton pump inhibitors, and those 
with extra-intestinal diseases as listed in Table 1.
Diagnosis
The choice of test for pre-treatment or never treated 
patients consists of non-invasive tests and invasive tests 
(Table 2). The non-invasive tests include carbon-13 urea 
breath test, serology for anti-H. pylori antibody, stool for 
H. pylori antigen, and urine for anti-H. pylori antibody. 
The invasive tests used during an upper endoscopy and 
biopsy include rapid urease test [with the commercial 
CLO test most commonly used], histology, culture, 
and polymerase chain reaction, with the later two very 
seldom performed. 
Table 2.  Diagnostic tests for Helicobacter pylori infection
Principle Post-
treatment
Costa Near 
patient 
testb
Remarksc
Invasive Tests
1. Rapid urease    
    test
urease ctivity +/- +++ Yes
2. Histology pathology 
assessment 
+ ++++ No
3. Culture microbiology + ++++ No Antibiotic 
sensitivity
4.  PCR genome + ++++ No Research
Non-invasive Tests
1. 13C-Urea 
    breath test
urease activity + ++ Yes/No
2. Stool Hp Antigen + + No
3. Serology Hp antibody - + No Need validation
4. Whole blood Hp antibody - + Yes Need validation
5. Urine Hp antibody - + Yes Need validation
a. Cost of invasive tests includes cost of upper endoscopy.
b. Near patient test means test that can be done within the doctor’s office and can    
    provide immediate result.
c. Tests that rely on antibody need to be locally validated in Hong Kong. The       
    accuracy may vary widely. 
The method of choice for non-invasive tests include 
urea breath test and stool antigen test. The serology 
tests rely on the accuracy of the test kit and not all test 
kits perform with the same accuracy. These tests are 
based on the ELISA method that requires the use of 
antigen epitopes from H pylori during production. 
Unfortunately H pylori from different countries or 
races have very diverse genomic variations. So some 
of the tests manufactured in USA or Europe based on 
Caucasian H pylori strains yield a very low accuracy for 
testing in Hong Kong1,2. The other form of serology test 
is the whole blood near patient test. The test uses only 
one drop of blood to be placed onto the test kit and the 
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doctor can read the result within minutes in the office. 
These tests have the same principle as serology test and 
the accuracy must be locally validated.
The method of choice for invasive tests include the 
rapid urease test and histology. Since the density of H 
pylori in the gastric antrum is the highest in normal 
patients without drugs, an antral biopsy is usually 
taken. However in patients on proton pump inhibitors, 
there is reduced density of H pylori in the antrum but 
with a higher density in the body and fundus. Therefore 
patients on PPIs should have biopsies from both the 
antrum and body to increase the accuracy.  
Recent intakes of PPIs and/or antibiotics produce false 
negative results for all tests except serology. False 
negative tests may result from these drugs that suppress 
bacterial growth. PPIs should be stopped at least 2 
weeks before performing the tests. Nowadays more and 
more patients are already receiving long term PPIs and 
cannot be withheld for various reasons. In this case, a 
locally validated serology test should be used. 
Post-treatment testing is generally performed 4-8 weeks 
after stopping all PPIs and antibiotics, the longer the 
better. Hence if there is no urgent need to perform 
the test, it should be done at 8 weeks after stopping 
treatment. For patients who have used both bismuth 
and PPIs in the treatment regime, most commonly in 
a second line treatment of H pylori, the test should 
be performed 8-12 weeks after stopping treatment, 
preferably 12 weeks. The test of choice is the urea breath 
test. An alternative is the stool Hp antigen test. Serology 
tests should never be used in post-treatment testing, 
as the antibody level will only be decreasing slowly 
despite successful treatment. In post-treatment testing 
for patients on long term PPIs, we still should not use 
serology test for the above mentioned reason. There 
is no single best method for these patients and clinical 
judgement is required in each scenario. 
Treatment
Standard First Line Treatment
For years, the use of triple therapy is the gold standard 
for first line treatment of H pylori infection. There are 
several recent guidelines with detailed description of 
the different regimens3,4,5. In principle, the eradication 
rate of any first line regimen should be above 90% 
by per protocol analysis (PP), or 80% by intention to 
treat analysis (ITT). The best regimen for most Asian 
countries is probably a PPI plus amoxicillin plus 
clarithromycin (Table 3). We have recently completed 
a local study and the combination of a PPI plus 
amoxicillin plus clarithromycin for 7 days is still the 
best regimen in Hong Kong with an eradication rate 
of 92.7%. Some guidelines recommend the treatment 
period be extended from 7 days to 10 days or even 14 
days, hoping to increase the eradication rate. Meta-
analysis has shown that this approach yields only small 
benefit, and yet the cost effectiveness, side effects and 
cost may need to be considered carefully. 
Treatment for Patients Allergic to Penicillin
For patients allergic to penicillin, the regime of choice 
will be a PPI plus clarithromycin plus metronidazole 
for 7 days. Due to increasing use of clarithromycin 
or metronidazole in monotherapy against other 
bacterial infections, it leads to increasing prevalence 
of antibiotic resistance in H. pylori. In Hong Kong, the 
antibiotic resistance of H pylori to clarithromycin and 
metronidazole is around 10% and 40% respectively and 
has remained stable in recent years. However we should 
be closely monitoring the pattern of resistance in future. 
The alternative for patients allergic to penicillin will 
be to use the quadruple therapy in the first line setting 
for 7 days. This will avoid the problem of resistance to 
clarithromycin and metronidazole, but carries a risk of 
very limited options remaining if the treatment is not 
successful.
Other Options
In view of increasing prevalence of resistance to 
clarithromycin and metronidazole, some countries have 
advocated the use of levofloxacin-containing triple 
therapy in first line treatment. We have completed a 
local study to assess the use of PPIs twice daily plus 
amoxicillin twice daily plus levofloxacin 500mg once 
daily. The eradication rate was 85.3% only6. Hence we 
concluded that levofloxacin-containing triple therapy is 
not suitable for use in Hong Kong as first line treatment 
at this moment. 
Second Line Treatment
For second line treatment of H pylori infection, the 
classical quadruple therapy is still the regimen of choice 
(Table 3). Our local study showed that the classical 
quadruple therapy with PPIs, bismuth subcitrate 240mg 
bid, metronidazole 400mg tds and tetracycline 500mg 
qds has an eradication rate of 88%. The use of a PPI plus 
bismuth plus amoxicillin 1000mg bid and levofloxacin 
500mg bid has an eradication rate of only 73% (P<0.05)7. 
The other rescue therapy is a PPI, rifabutin 300mg 
daily, levofloxacin 500mg daily for 7 days. It had an 
eradication rate of 91%8. However rifabutin may have 
a rare chance of neutropenia and thrombocytopenia 
which restrict its use in this setting.
Table 3.  Treatment regimes for H. Pylori infection
First line treatment
1.
2.
3.
4.
PPI standard dose + amoxicillin 1 gram + clarithromycin 500mg, 
all twice daily for 7 days (up to 14 days)
PPI standard dose + metronidazole 400mg + clarithromycin 
500mg, all twice daily for 7 days, (up to 14 days) (for patient 
allergic to penicillin)
PPI standard dose + amoxicillin 1 gram + metronidazole 400mg, 
all twice daily for 7 days, (up to 14 days)(for patients allergic to 
clarithromycin, or cost concern)
PPI standard dose twice daily + bismuth 240mg twice daily + 
metronidazole 400mg three times daily + tetracycline 500mg 
four times daily for 7 days (up to 14 days) (for patient allergic to 
penicillin)
Second line treatment for H. Pylori infection
1. PPI standard dose twice daily + bismuth 240mg twice daily + 
metronidazole 400mg three times daily + tetracycline 500mg four 
times daily for 7 days (up to 14 days)
PPI standard dose: Omeprazole 20mg, lansoprazole 30mg, 
pantoprazole 40mg, rabeprazole 20mg, esomeprazole 20mg
In this regard, it is of importance to emphasise good 
compliance during both first and second line treatment. 
Most of the drop outs are usually due to minor adverse 
effects such as loose stool, altered taste, malaise etc. It 
is important to encourage the patients to complete the 
whole course of treatment and reassure them that these 
minor adverse effects are tolerable, and will disappear 
after finishing the regimen. It is still important to be 
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on the alert for pseudo-membranous colitis due to 
the use of amoxicillin. Patients should be reminded to 
contact the physician urgently if there is profuse watery 
diarrhoea during the course of treatment. 
Conclusion
Although there are several new regimens proposed 
for the treatment of H pylori infection, the classical 
triple and quadruple therapy are still the best for first 
and second line treatment respectively. It is important 
to ensure patient compliance to enhance the high 
eradication rate.
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Background
An estimated 170 million people worldwide are infected 
with the hepatitis C virus (HCV).1 The majority of these 
people will remain asymptomatic at the time of acute 
infection; therefore HCV infection is rarely diagnosed 
during the acute phase.2 In those subjects acutely 
infected with HCV, approximately 50-85% will become 
chronically infected, of which around 20% will progress 
to cirrhosis over the course of 15-20 years.3 In fact, 
HCV has become one of the major indications for liver 
transplantation in the Western world. 
Currently Available Agents
The current standard treatment for chronic hepatitis C 
(CHC) is pegylated interferon (peg-IFN) α-2a or α-2b 
in combination with ribavirin (RBV). In a randomised 
trial (the IDEAL study) of these two forms of peg-
IFN, efficacy and side-effect profiles were similar.4 The 
ultimate goal of antiviral therapy is the achievement of 
sustained virological response (SVR), which is defined 
by undetectable HCV RNA by a sensitive molecular 
assay at 6 months after the completion of antiviral 
therapy, and is considered as a cure. Achievement of 
SVR is associated with improvement of fibrosis stage, 
reduced incidence of hepatocellular carcinoma, and 
decreased morbidity and mortality.5 The exact antiviral 
mechanism of peg-IFN-α is not known. RBV is a 
guanosine analog with low antiviral potency against 
HCV when used alone.6-8 However, its antiviral effect is 
augmented when used together with IFN although the 
mechanism of this synergism is not known.9, 10
HCV can be  divided into  6  major  genotypes , 
numerically named from 1 to 6 according to their time 
of discovery. These genotypes display differences 
in their geographical distribution, with genotype 1 
and 6 being the most prevalent in Hong Kong.11 The 
majority of genotype 1 patients are infected through 
blood transfusion, whereas a larger proportion of 
genotype 6 patients are infected through the use of 
intravenous drug abuse.12 Apart from their differences 
in distribution, the other major difference between the 
genotypes is their responses to antiviral therapy. 
Genotype 1
In patients infected with HCV genotype 1,  the 
recommended duration of treatment is 48 weeks, 
with a SVR of approximately 50-55%.13-15 The level of 
HCV RNA is assessed at week 12 for early virological 
response (EVR), which can be defined as complete 
(undetectable HCV RNA) or partial (≥2 log decrease 
in HCV RNA from baseline). For those patients who 
cannot achieve EVR, the negative predictive value for 
treatment outcome is high at 97%, and the chance of 
going on to achieving SVR with 48 weeks of therapy 
is unlikely.13 In patients who fail to reach EVR at week 
12, early treatment discontinuation is recommended as 
these patients are likely to be non-responders. For those 
patients who achieved EVR, an estimated 65-72% will 
go on to achieve SVR.13, 16
More recently, the use of rapid virological response 
(RVR), defined by undetectable HCV RNA at week 4 
using sensitive molecular tests, has been evaluated to 
identify a subgroup of patients who may benefit from a 
shorter duration of therapy. Several trials have shown 
that in genotype 1 patients who achieve RVR, a high 
SVR rate of over 70% can be achieved with peg-IFN plus 
ribavirin with a shorter duration of treatment for 24 
weeks, which was comparable to those that were treated 
for 48 weeks.17-21 The major factor determining the 
outcome in patients with RVR and shorter duration of 
therapy was the level of viraemia at baseline. However, 
there is currently no consensus as to the baseline cut-off 
HCV RNA level that can be adopted to select out those 
who will be sufficiently treated with 24 weeks, although 
various cut-offs of 400,000, 600,000, and 800,000 IU/
mL have been evaluated. Further trials are needed to 
identify an optimal cut-off level before shorter duration 
of therapy can be implemented. 
On the opposite end of the spectrum, there have been 
studies evaluating longer duration of treatment. In an 
earlier trial looking at 48 vs 72 weeks of treatment in 
genotype 1 patients, there was no significant difference 
observed in SVR rates, although a higher SVR rate was 
observed in those who failed to achieve complete EVR 
at 12 weeks with 72 weeks of treatment.22 Those patients 
who did not achieve RVR also had a higher SVR rate 
when treated for 72 weeks compared to 48 weeks.23 
However, more recent trials have not shown the benefits 
of 72 weeks of treatment when compared with 48 weeks. 
In patients who achieve partial EVR (but not complete 
EVR), there was no significant increase in SVR observed 
with 72 weeks of therapy compared with 48 weeks.24 
Another study also showed no significant difference 
in SVR rates between 48 and 72 weeks of therapy in 
patients with genotype 1/4 who achieved either partial 
or complete EVR.25 
Genotypes 2 and 3
In patients infected with HCV genotype 2 or 3, the 
recommended treatment length is 24 weeks, with a 
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SVR rate of 70-75%.15, 26 Given that most patients will 
achieve EVR, and coupled with a shorter duration of 
therapy (compared to genotype 1), the use of EVR at 
week 12 to determine treatment outcome has not been 
adopted. Similar to the recent approaches for genotype 
1 patients, both shortening and extending the duration 
of therapy have been evaluated in patients infected 
with genotype 2/3. 
In the ACCELERATE trial comparing 16 vs 24 weeks of 
therapy, those treated for 16 weeks resulted in a lower 
SVR rate.27 For patients with HCV genotype 2/3 (the 
NORDynamIC study), treatment length of 12 weeks was 
inferior to 24 weeks of therapy.28 However, in patients 
who achieved RVR at week 4, 12 weeks of therapy 
was shown to be as effective as 24 weeks of therapy.29 
Another study showed similar results with 16 weeks 
of therapy, although those patients infected with HCV 
genotype 3 and a high baseline viral load (>800,000 IU/
mL) showed a lower SVR with 16 weeks of therapy 
compared with 24 weeks.30 Patients infected with HCV 
genotype 2 who achieved RVR appeared to show equal 
efficacy when treated for either 16 or 24 weeks.31 A 
meta-analysis of trials evaluating shorter duration of 12-
16 weeks in genotype 2/3 patients with RVR showed an 
association with a lower SVR rate and higher relapse 
rates.32 Given the heterogeneity of these studies it is 
difficult to recommend a shorter duration of therapy for 
patients infected with genotype 2/3, although those who 
achieve RVR would appear to benefit most. 
Genotype 6
There is currently no randomised controlled trial for 
genotype 6, therefore the recommendation is to treat 
these patients for 48 weeks. In retrospective studies 
comparing genotypes 6 and 1, the SVR rates were 
significantly higher in genotype 6 compared to genotype 
1 when treated for 48 weeks.33, 34 However, another 
retrospective study showed that 24 weeks of treatment 
was inferior to 48 weeks of treatment for genotype 6.35 
Non-responders to Therapy
In patients who do not respond to peg-IFN plus RBV 
therapy, the HALT-C study showed that further 
prolonged maintenance therapy with low-dose peg-
IFN did not significantly reduce the rate of disease 
progression despite significant decline in HCV RNA.36 
However, studies of re-treatment with a limited 
duration have shown some benefits. In the REPEAT 
study, re-treatment with peg-IFN-α2a + RBV for 72 
weeks achieved a higher SVR rate compared to 48 
weeks, although the SVR rate was still low at 16%.37 
The EPIC3 study also showed a SVR of 22% in patients 
re-treated for 48 weeks with peg-IFN-α2b + RBV.38 
Therefore, re-treatment appears to be beneficial in 
subgroups of patients who have failed previous 
treatments with peg-IFN. However, there is no current 
recommendation for retreatment of patients who have 
completed a full course of peg-IFN + RBV therapy.39
Side-effects of Current Therapy
Prior to commencing antiviral therapy, a full medical 
history and examination must be obtained as there can 
be potential for serious adverse effects. Since immune 
stimulation by peg-IFN may induce severe liver injury, 
treatment for patients with established cirrhosis should 
be considered carefully, and is contra-indicated in 
those with decompensated cirrhosis. The side-effects 
of hepatitis C therapy are summarised in table 1. 
Because of the possible serious adverse events, patient 
selection is of utmost importance, and the decision to 
treat requires a careful assessment of the risk to benefit 
ratio for each individual patient. Patients should also be 
aware of the possible worsening of their quality of life 
during the course of the treatment. 
Table 1. Common side effects of pegylated interferon and 
ribavirin therapy
Flu-like symptoms Haematological
    Fatigue     Anaemia
    Myalgia     Leucopenia
    Pyrexia     Thrombocytopenia
    Rigours
    Headache Autoimmune
    Arthralgia     Thyroid disorder
    Other autoimmune disorders
Mood disturbances
    Depression Dermatological
    Irritability     Rash
    Memory loss     Exacerbation of psoriasis
    Mood swings     Injection site reaction
    Insomnia     Alopecia
Interferon
Patients who experience flu-like symptoms may 
respond to treatment with acetaminophen or non-
steroidal anti-inflammatory drugs, whereas those with 
insomnia may be treated with sleeping medications. 
Although neutropenia is commonly observed in patients 
treated with IFN, the risk of infection is low, and careful 
monitoring usually suffices.15, 40 The use of granulocyte 
colony-stimulating factor is only rarely considered. 
Thrombocytopenia is commonly observed in patients 
with liver disease secondary to both hypersplenism 
and insufficient hepatic production of thrombopoetin. 
This can be further compounded by the administration 
of IFN-based therapy, which is associated with a 
rapid and sustained reduction in peripheral platelet 
count. Currently there is no approved agent available 
for the treatment of thrombocytopenia, although 
thrombopoetin-mimetic agents such as eltrombopag 
may become available in the near future. 
Ribavirin
The most significant adverse effect of ribavirin is 
haemolytic anaemia, which is commonly observed in 
patients undergoing treatment. Management includes 
reducing the dose of ribavirin if the haemoglobin level 
falls below 10 g/dL, or stopping therapy if it falls below 
8.5 g/dL. Ribavirin may need to be avoided in patients 
who cannot tolerate anaemia, such as those with pre-
exiting cardiovascular or cerebrovascular diseases. The 
use of erythropoietin is effective in treating anaemia and 
ameliorating the need for dose reduction of ribavirin, 
and in improving the quality of life of patients.41,42 
However, the effect on improved SVR is yet to be 
demonstrated. As there is associated teratogenicity with 
ribavirin, it is contra-indicated during pregnancy, and 
adequate contraception must be adopted for both male 
and female patients. 
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Future Therapeutic Agents in HCV 
Treatment
As described previously, with the current standard 
of care using peg-IFN and ribavirin, only around 50% 
of patients with genotype 1 may achieve SVR. Newer 
agents are much anticipated to improve the modest cure 
rate. Newer types of IFN are undergoing evaluation, 
including consensus IFN and albuferon.43, 44 Novel 
deliveries of IFN include controlled release formulations 
and the uses of nanoparticle delivery systems are also 
being explored. 
Currently, there are many promising agents known as 
specifically targeted antiviral therapy for hepatitis C 
(STAT-C) compounds which target the HCV replication 
cycle are undergoing phase I to III trials.  Two of 
these STAT-C agents, telaprevir and boceprevir, are in 
advance stages of development, and should become 
available in the following 1-2 years.   
Telaprevir
Telaprevir is an oral NS3 protease inhibitor currently 
undergoing phase III evaluation. In the initial phase 
I studies, an optimal dose of 750mg q8h following 
an initial loading dose of 1250mg was identified.45,46 
Selection of telaprevir-resistant mutations was 
observed with telaprevir monotherapy, although the 
rate was significantly lower when combined with peg-
IFN. In the phase II trial of treatment-naïve genotype 1 
patients (PROVE 1 study in USA and PROVE 2 study 
in Europe), those treated with 12 weeks of telaprevir 
had a significantly higher SVR rate when treated with 
24 or 48 weeks or Peg-IFN + ribavirin compared to 
standard therapy of 48 weeks of peg-IFN + ribavirin 
without telaprevir.47, 48  These two trials also showed 
that 12 weeks of therapy using telaprevir, peg-IFN, and 
ribavirin was associated with a high relapse rate. The 
PROVE 2 trial also showed that those treated without 
ribavirin was associated with a lower SVR rate.48 In the 
trial of treatment-experienced patients (the PROVE 3 
study), re-treating non-responders with 12 weeks of 
telaprevir + peg-IFN + ribavirin for 12 weeks followed 
by a further 12 weeks of peg-IFN + ribavirin resulted 
in a SVR rate of 51%, compared to 14% in patients re-
treated with peg-IFN + ribavirin without telaprevir.49 
A number of phase III trials are currently in progress 
for treatment-naïve patients (the ADVANCE and 
ILLUMINATE study) and for patients with previous 
treatment failure (the REALISE study). The most 
common side effects of telaprevir include rash, 
gastrointestinal disorders, and anaemia.
Boceprevir
Boceprevir is a NS3 protease inhibitor, another STAT-C 
compound that is currently undergoing phase III 
evaluation. In the phase II trial (the SPRINT 1 study) 
of treatment-naïve genotype 1 patients, those patients 
receiving boceprevir had higher rates of SVR compared 
to patients treated with peg-IFN + ribavirin without 
boceprevir.50 Common side-effects included anaemia 
and gastrointestinal symptoms. Boceprevir is currently 
being evaluated in phase III trial of treatment-naïve 
genotype 1 patients (the SPRINT 2 study) using 
boceprevir 800mg tds + peg-IFN α-2b + ribavirin for 
28/48 weeks versus standard treatment with peg-IFN 
α-2b + ribavirin for 48 weeks. The other phase III trial 
is on relapsers and non-responders (the RESPOND-2 
study) using boceprevir 800mg tds + peg-IFN α-2b + 
ribavirin for 36/48 weeks versus standard treatment 
with peg-IFN α-2b + ribavirin for 48 weeks. Similar 
to telaprevir, there are also mutations associated with 
boceprevir treatment. 
Apart from telaprevir and boceprevir, there are 
currently a host of other NS3/4A protease inhibitors 
undergoing phase I and II evaluations. In addition to 
the NS3/4A protease inhibitors, other classes of antiviral 
compounds undergoing phase I and II development 
include the NS5B polymerase inhibitors and NS5A 
inhibitors. 
Summary
Over the recent years, there has been a shift towards 
individualisation of treatment according to their initial 
responses to therapy. There have been many studies 
evaluating shortening of therapy in patients who 
achieve RVR and also those with lower baseline viral 
load. However, further studies are still needed to clarify 
the optimal modified duration of therapy and also the 
optimal baseline viral load at which these truncated 
treatment regimens can be implemented. For those 
patients who do not respond to therapy, extending 
the duration of therapy may not improve the chance 
of achieving SVR. Fortunately there are now many 
newer agents in various stages of development to treat 
patients infected with genotype 1 and those patients 
who have failed peg-IFN + RBV therapy. Both telaprevir 
and boceprevir are undergoing phase III evaluation 
and should become available in the very near future. 
Because of the high risk of resistant mutations when 
used as monotherapy, these newer agents will be used 
in combination with peg-IFN + RBV or with other newer 
STAT-C compounds as they become available. 
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Introduction
Hepatocellular carcinoma (HCC) is one of the most 
common malignancies, ranking fifth in frequency among 
all malignancies in the world.1 HCC is characterised by 
rapid tumour growth and a high propensity of vascular 
invasion. Furthermore, 80% of patients with HCC have 
associated liver cirrhosis related to hepatitis B or C 
viral infection, which often restricts treatment options 
because of impaired liver function. The prognosis of 
untreated HCC is poor, but the management approach 
of HCC has changed from a previously nihilistic 
approach to a more aggressive one with recent advances 
in management, resulting in improved prognosis. The 
wider utilisation of screening programme in high-risk 
patients has resulted in early detection of small HCCs, 
and thus improved chance of treatment.2 Compared 
with other gastrointestinal cancers, management of 
HCC is more complicated because of the wide range 
of treatment modalities available and the underlying 
liver disease. Appropriate selection of patients for 
individual treatment according to tumour status 
and liver function is critical to optimise treatment 
outcome, and some patients may require combination 
of modalities in management. Treatments for HCC can 
be classified into curative (resection, transplantation or 
ablation) or palliative (transarterial chemoembolisation, 
radioembolisation or systemic therapy). 
Surgical Resection
Hepatic resection is the treatment of choice for patients 
with HCC and preserved liver function.  Even for 
patients with a large HCC > 10 cm in diameter, resection 
is safe and offers favourable long-term survival results.3 
The presence of multiple tumour nodules or vascular 
invasion in major intrahepatic venous branches may 
be associated with worse prognosis. However, surgical 
resection is still considered the best treatment in terms 
of long-term survival.4 Extended right or left hepatic 
resection can be performed even in the presence of 
cirrhosis, provided patients are carefully selected in 
terms of liver functional reserve.5 In patients with 
inadequate remnant liver volume for a right or extended 
right hepatectomy, preoperative right portal vein 
embolisation can be employed to induce atrophy of the 
right lobe and hypertrophy of the liver remnant before 
resection. In centres specialised in hepatobiliary surgery, 
liver resection for HCC is now a safe operation with an 
operative mortality 2-5%.6 Major complications such as 
massive bleeding or postoperative liver failure are rare 
with careful patient selection and modern operative 
techniques. 
In recent years, laparoscopic liver resection has 
become feasible with the development of laparoscopic 
instruments that allow liver transection without major 
bleeding. Tumours in anterior segments or left lateral 
segments can be resected using a laparoscopic approach, 
with the benefit of less postoperative wound pain, better 
cosmetic result, shorter hospital stay and faster recovery 
(Figure 1). A meta-analysis of retrospective comparison 
of laparoscopic and open approach has shown reduced 
blood loss with the laparoscopic approach, while 
oncologic clearance in terms of resection margin was 
similar between the two groups. 
Figure 1. A patient with a small left lateral segment HCC (Fig. 
1a) treated by laparoscopic left lateral sectionectomy (Fig. 1b). 
Blood loss was only 100 ml and the patient was discharged 
uneventfully two days after operation. 
Bilobar HCC was used to be a contraindication for 
resection. However, with the advent of thermal ablation 
therapy, it is now possible to perform combined 
resection of predominant tumour mass(es) in one lobe 
and ablation of small tumour nodule(s) in the other lobe 
(Figure 2). Such an aggressive approach has increased 
the chance of patient receiving curative therapy for HCC 
and could achieve similar survival results compared 
with resection alone. 
Figure 2. A patient with bilobar HCC (Fig. 2a, three tumours in 
right lob and one in left lateral segment) deemed unresectable 
by a hepatologist and treated with TACE. He was complicated 
by a right lobe liver abscess in one of the tumour in the right 
lobe (Fig. 2a, arrow). He was subsequently treated by the 
author with right hepatectomy and intraoperative RFA of the 
left lobe tumour (Fig. 2b), and he recovered uneventfully.
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Improvement in long-term survival results after 
resection of HCC has also been observed in recent 
years, with 5-year survival rate now exceeding 50%.7 
The improvement in survival could be attributed to 
the increased diagnosis of early HCC and reduction 
in perioperative blood transfusion. Perioperative 
transfusion has been found to have an adverse impact 
on the long-term survival after resection of HCC by 
an inhibitory effect on immune system that leads to 
increased risk of recurrence. Hence, the surgeon can 
play an important role in improving the long-term 
prognosis by minimising intraoperative blood loss 
and avoiding perioperative transfusion. The long-term 
prognosis after resection of HCC has been limited by 
a high incidence of postoperative recurrence due to 
metastatic lesions or multicentric recurrences in the liver 
remnant.8 Postoperative adjuvant systemic or regional 
chemotherapy has so far failed to prevent recurrence 
in prospective clinical trials. Aggressive treatment 
of recurrent tumours by re-resection or non-surgical 
modalities such as percutaneous ablation therapy can 
result in prolonged survival even after the development 
of recurrent tumours.
Liver Transplantation
In the 1980s, advanced unresectable HCC was a 
common indication for transplantation but the results 
were disappointing, with a 5-year survival rate of 
around 20%.9 The presence of circulating tumour 
cells associated with large HCC leads to a high 
incidence of postoperative recurrence in the setting 
of immunosuppressive therapy used to prevent graft 
rejection. A landmark study published in 1996 showed 
that for solitary HCC < 5 cm or < 3 tumour nodules 
each of size < 3 cm, the long-term survival rate of liver 
transplantation was favourable.10 It is now well-accepted 
that Child’s C cirrhotic patients with HCC < 5 cm or < 3 
tumour nodules each of size < 3 cm (Milan criteria) and 
without radiological evidence of venous invasion or 
distant metastasis should be treated by transplantation, 
as hepatic resection is usually contraindicated in this 
group of patients with poor hepatic function. Some 
centres adopted expanded criteria of solitary tumour 
≤ 6.5 cm or ≤ 3 nodules with the largest lesion ≤ 4.5 cm 
and total tumour diameter ≤ 8 cm (UCSF criteria) for 
liver transplantation.11 With such stringent selection 
criteria, the 5-year survival rate is about 60-75%. 
Tumour recurrence is an important cause of long-term 
mortality after liver transplantation. Currently there 
is no effective adjuvant therapy to reduce the risk of 
tumour recurrence. 
Whether Child’s A cirrhotic patients with preserved 
liver function and a small HCC should be treated with 
transplantation or resection is a controversial issue. Some 
Western centres recommended liver transplantation 
for small HCC even in child’s A patients because of the 
lower tumour recurrence rate compared with resection. 
However, in most Asian centres including Hong Kong 
where there is a severe shortage of liver graft donors, 
hepatic resection remains the first-line treatment for 
such patients because similar overall survival results of 
about 70% in 5 years can be achieved for small HCCs.12 
A significant proportion of HCC patients listed for 
liver transplantation may drop out of the waiting list 
because of tumour progression. Furthermore, specific 
long-term complications of liver transplantation such as 
recurrent viral hepatitis, graft rejection, opportunistic 
infection or secondary malignancies as a result of 
immunosuppression may lead to mortalities. Resection 
followed by salvage transplantation for intrahepatic 
recurrence or deterioration of liver function may be a 
more effective strategy for patients with small HCC and 
preserved liver function.12
Adult live donor liver transplantation is an appealing 
alternative for patients with HCC because it reduces 
the chance of dropout from the waiting list for deceased 
donor liver grafts. However, the benefit of live donor 
liver transplantation for HCC patients has to be 
balanced against a risk of about 0.5% mortality and 20% 
morbidity in the live donor undergoing right lobe donor 
hepatectomy.13 Furthermore, there is some concern 
of the effect of regeneration of the partial liver graft 
in stimulating the growth of microscopic metastasis, 
although there are not enough clinical data on this 
issue. Hence, most centres consider that the selection 
criteria for HCC patients to undergo live donor liver 
transplantation should be similar to that of deceased 
donor liver transplantation. Even with the use of live 
donor liver transplantation, less than 5% of HCC 
patients at the author’s institution are treated by liver 
transplantation.
Local Ablative Therapies
Local ablation is a potentially curative therapy for small 
HCCs not amenable to resection. Patients with HCC 
≤ 5 cm and up to 3 nodules are the best candidates for 
ablative therapies, although larger tumours can also be 
ablated in selected cases. While there is some preliminary 
evidence suggesting that ablative therapies may 
achieve similar survival results compared with surgical 
resection,14,15 the evidence is not yet strong enough to 
recommend local ablation as the first line therapy for 
patients with a resectable small HCC. However, for 
patients with borderline liver function, local ablation 
is a safer option especially if the tumours are centrally 
located. Local ablative therapies are useful in treating 
recurrent HCC after previous resection, which occurs 
mostly in the liver remnant. Local ablative therapy may 
also be employed as a bridging therapy for control of 
tumours before a liver graft is available even if liver 
transplantation is contemplated. 
Percutaneous ethanol injection therapy was used to be 
the main local ablative therapy in the 1990s. However, 
radiofrequency ablation (RFA) has replaced ethanol 
injection to be the most widely used ablative modality for 
HCC. Randomised controlled trials have demonstrated 
that RFA is superior to ethanol injection in that it requires 
fewer treatment sessions, and it achieves a higher 
complete ablation rate, lower tumour progression rate 
and higher overall survival rate.16,17 RFA is associated 
with a mortality rate of 1% or lower, and it can be 
performed through percutaneous, laparoscopic, and open 
approaches. The choice of treatment approach depends 
on the size and location of the tumour(s) and patients’ 
comorbid condition. Patients with tumour ≤ 3 cm in 
diameter located in the periphery of the liver are the best 
candidates for percutaneous RFA under ultrasonographic 
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or computed tomography guidance. Laparoscopic RFA 
allows the ablation of liver tumours in close contact 
with the surrounding organs, such as bowel, kidney, 
gallbladder and diaphragm, for which percutaneous RFA 
carries the risk of bowel perforation or visceral damage. 
Open surgical approach is indicated in patients with 
large tumours or multiple tumour nodules located at the 
superior or posterior portion of the liver (Figure 3). There 
is a higher degree of freedom for accurate introduction 
of the RF needle into the tumour in open RFA compared 
with other approaches, so that more effective ablation 
can be carried out to minimise the chance of residual 
tumour at the treatment site. For HCC > 3 cm in diameter, 
a previous study by the author showed that open 
approach achieved better long-term survival compared 
with percutaneous RFA.18 Recent studies have shown 
that 5-year survival of 40-60% can be achieved with 
RFA for small HCCs, but the recurrence rate remains 
high. The author is conducting randomised controlled 
trials to evaluate the benefit of combining transarterial 
chemoembolisation (TACE) or heat-activated liposomal 
doxorubicin (Thermodox) in combination with RFA to 
reduce recurrence rate. Thermodox contains doxorubicin 
encapsulated in a heat-sensitive layer of liposome that 
releases the doxorubicin at temperature > 42OC. This 
allows delivery of high concentrations of doxorubicin 
to the ablation zone with minimal systemic toxicity. An 
early phase trial jointly conducted by the author and the 
National Cancer Institute of the USA showed that this is 
a promising strategy in enhancing cancer killing at the 
ablation zone.19
Figure 3. A 5-cm HCC at the dome of the right liver (Fig. 3a) 
treated by open RFA (Fig. 3b). Postoperative contrast CT scan 
showed complete ablation (Fig. 3c).
High intensity focused ultrasound (HIFU)  is a new 
modality of ablation that is totally non-invasive. 
Ultrasound focused by a transducer can kill cancer cells 
by cavitation effect in addition to thermal ablation effect. 
Currently, Queen Mary Hospital is the only hospital in 
Hong Kong with a HIFU system for treatment of liver 
cancer. Since 2007, more than 100 cases of HIFU for 
HCC have been performed under ultrasound imaging 
guidance, with complete ablation rate close to that of 
RFA. As no electrode needle puncture is required, it 
eliminates the small risk of bleeding or needle track 
tumour cell seeding associated with RFA. Furthermore, 
the ablation is more precise than RFA and it may be used 
in tumours located near major bile duct or vessels. It is 
also possible to ablate large tumours > 5 cm (Figure 4). 
Figure 4. A 6.8 cm HCC in right lobe (Fig. 4a) treated with HIFU. 
Post-ablation MRI scan showed complete ablation (Fig 4b).
Transarterial Therapies
For patients with large tumour or multifocal tumours 
confined to the liver but not suitable for resection, 
transplantation or ablation because of inadequate liver 
function reserve or poor general condition, transarterial 
chemoembolisation (TACE) is the standard of care. In 
this treatment, cisplatin or doxorubicin mixed with 
Lipiodol is injected to the hepatic artery supplying the 
tumour(s) via a catheter placed through the femoral 
artery, followed by embolisation using gelfoam or 
embosphere particles. Meta-analyses of prospective 
randomised trials have demonstrated the efficacy of 
TACE in prolonging the survival of patients compared 
with conservative management, but the tumour 
response rate is only about 35%.20 Revascularisation 
by angiogenenesis in the periphery of tumour after 
initial response leads to disease progression. Molecular 
targeting agents such as bevacizumab, which is a 
monoclonal antibody against vascular endothelial 
growth factor,  have been developed to inhibit 
angiogenesis. Anti-angiogenic therapy has been proven 
to be a useful treatment to inhibit cancer growth in 
several human cancers.  The author is conducting a 
trial of combining bevacizumab with TACE to enhance 
its efficacy. 
Doxorubicin-eluting bead is a new development that 
aims to enhance the efficacy of TACE and reduce its 
toxicity. The beads are microspheres pre-loaded with 
doxorubicin that releases the doxorubicin slowly in the 
tumour when injected transarterially and the beads 
also serve as embolising particles. A phase I/II study 
conducted by the author showed that doxorubicin-
eluting bead could significantly reduce the systemic 
exposure to doxorubicin while delivering higher 
concentration of doxorubicin to the tumour compared 
with conventional Lipiodol-doxorubicin TACE, and 
the tumour response rate appeared superior.21 A 
randomised trial in Europe has shown that doxorubicin-
eluting beads reduced liver toxicity and increased 
tumour response in more advanced HCC compared 
with conventional Lipiodol-TACE.22
Transarterial radioembolisation using Yttrium-90 
labelled spheres is an alternative to TACE that has 
become more popular in recent years, though its use 
is still limited compared with TACE. The efficacy and 
safety of transarterial radioembolisation appears to be 
similar to TACE, but there are no randomised trials 
comparing it with TACE in the literature. Transarterial 
radioembolisation appears to be more effective in 
inducing shrinkage of tumour thrombus in the portal 
vein compared with TACE.23,24 The author prefers to 
use transarterial radioembolisation rather than TACE 
in patients with portal vein tumour thrombus and had 
experience of successful shrinkage of tumour thrombus 
in main portal vein followed by resection. 
Systemic Therapy
For patients with advanced HCC that is not amenable 
to locoregional therapy, systemic chemotherapy has so 
far demonstrated low efficacy and toxicity is significant 
because of the underlying cirrhosis in most patients. 
Systemic chemotherapy suing conventional agents 
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such as 5-FU, doxorubicin and cisplatin either alone or 
in combination has not been shown to prolong patient 
survival in prospective randomised trials.25,26 HCC is 
a highly vascularised tumour, and previous studies 
by the author have demonstrated that significance of 
angiogenesis and vascular endothelial growth factor 
in HCC.27,28 Recently, a molecular targeting agent that 
inhibits receptor of vascular endothelial growth factor 
and a signalling protein Raf kinase in the HCC cells 
has been shown to be effective in prolonging survival 
of patients with advanced HCC in two large phase 
3 randomised placebo-controlled trials.29,30 The drug 
Sorafenib prolonged patient survival by approximately 
three months in these trials, but tumour response rate 
was less than 3%. Hence, the benefit is limited. The use 
of Sorafenib is also hindered by significant side effects 
such as hand-foot skin reaction and the high cost. 
Currently many other molecular targeting drugs 
that target different pathways such as the mTOR 
pathway, c-MET and fibroblast growth factor are under 
clinical trials in direct comparison with Sorafenib, in 
combination with Sorafenib or as a second-line therapy 
after Sorafenib failure.31 Some novel drugs such as 
Everolimus and Brivanib have demonstrated favourable 
safety and also efficacy in phase II trials in HCC and 
are now being evaluated in phase III trials.31 In the 
author’s institution, several clinical trials on the novel 
drugs are on-going (information available on www.
livercancer.hku.hk) and provide an alternative option 
for patients who cannot afford Sorafenib or who have 
failed Sorafenib therapy. The author has also completed 
a phase II trial of combining Sorafenib with newer 
chemotherapeutic agents Capecitabine and Oxaliplatin 
(SECOX) for advanced HCC. Our data showed that the 
regimen is well-tolerated in HCC patients and appears 
to be substantially superior to Sorafenib monotherapy 
in tumour response rate, disease stabilisation rate and 
overall survival. An international multi-centre phase 
III randomised controlled trial will be conducted to 
further evaluate the benefit of this regimen compared 
with Sorafenib monotherapy. Finally, the role of 
molecular targeted agents in earlier stage HCC is also 
being evaluated. The author is participating in a large-
scale international multi-centre phase III randomised 
trial of Sorafenib versus placebo as adjuvant therapy 
after resection or ablation of HCC, with a target sample 
size of 1100 patients. There are also on-going trials of 
combination of Sorafenib or novel targeting agents such 
as Brivanib with transarterial chemoembolisation for 
intermediate stage HCC.
Conclusions
The management of HCC has changed dramatically in 
recent years with improved outcomes. The improved 
safety and long-term survival after hepatectomy for 
HCC and the development of minimally invasive liver 
resection have reinforced the role of liver resection 
as the first-choice treatment. Local ablative therapies 
have provided an important alternative for curative 
treatment for patients who have inadequate liver 
function reserve for resection. Recurrence after resection 
or ablation remains a major problem, but active 
studies are being conducted to evaluate novel adjuvant 
therapies to improve the prognosis of patients. TACE 
or radioembolisation is the mainstay of palliation for 
patients whose HCCs are confined to the liver that is 
not amenable to resection or ablation. Occasionally, 
patients with initially unresectable disease can be down-
staged to resectable disease after transarterial therapies. 
Development of novel techniques such as drug-eluting 
beads and combination with molecular targeting drugs 
may further enhance the efficacy of TACE. Molecular 
targeted therapy is an important break-through that 
has shown for the first time as a systemic therapy to 
improve survival of patients with advanced HCC. It has 
triggered major interests in development of new drug 
therapies that hopefully will help conquer a disease 
once deemed to be associated with uniformly grim 
prognosis.
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Voluntary Health Protection Scheme: the 
right choice for the next step of Hong Kong’s 
healthcare reform? 
Prof. Geoffrey LIEU
Prof. Geoffrey LIEU
The voluntary Health Protection Scheme (hereafter, 
the Scheme) proposed by the Hong Kong Special 
Administrative Region Government (HKSARG) in the 
consultation document My Health My Choice1 is a form 
of the traditional individual private indemnity health 
insurance or fee-for-service plan that many healthcare 
systems in the world are shunting or have dropped in 
favour of other forms of health insurance. In the United 
States, for example, where private indemnity health 
insurance dominated between the 1960s to 1980s, such 
traditional plans have dwindled and are now rarely 
offered in its original form due mainly to its high cost 
arising from, among other things, warped incentives for 
both consumers and providers.  
As it is presented for public consultation, it should be 
relevant to review the pros and cons of the Scheme 
and focus on the question: Is the proposed scheme the 
right choice for the next step of Hong Kong’s healthcare 
reform?  To answer this question, one should need 
to have at least two other questions answered first: 
What kind of future healthcare financing and payment 
systems do we want or should best befit Hong Kong 
in the long term, say 20 or 30 years from now?  What 
or how will the proposed Scheme address Hong Kong 
residents’ current and future healthcare concerns?  
 
The right healthcare financing and 
payment systems for Hong Kong 
What healthcare financing arrangements Hong Kong 
should adopt should fundamentally be premised on the 
healthcare system that we want in the future.  Although 
it has never been precisely clear, it is suggested in the 
current as well as previous consultation documents that 
we should want an effective and sustainable healthcare 
system that:  
• ensures equitable access with the public system 
providing a safety net for all; and 
• provides adequate choice through a private sector 
that is equally professional and transparent (as the 
public sector) to consumers in both quality and 
service fees.2 
The right words are mostly there.  But what do they 
mean and how do they work in practice?  What conjures 
up in our minds as the way it will and should work 
may be very different. Our concerns, thoughts and 
behaviours, including those of our close ones, are very 
different before we are sick and while we are sick.  Then, 
of course, consumers, patients and providers can have 
divergent perspectives, wants, needs and demands that 
may be difficult to align. 
The vision of the healthcare system that we should 
want has largely been defined top down. We have been 
persuaded to share the view that a comprehensive 
reform is needed because: 
“  …ageing demographic  prof i le  of  the 
population and rising medical costs due to 
advancement in medical technology would 
pose significant challenges to the healthcare 
system.   The ageing population would lead to 
rapid increase in healthcare needs and services 
demands on the healthcare system, particularly 
the public system. The cost of healthcare 
would also likely continue to rise in view of 
the advancement of medical technology and 
medical inflation….The significant public-
private imbalance in our healthcare system…
could lead to deterioration of service quality 
and lengthening of waiting queue for highly-
subsidised public healthcare services, where 
the elderly, chronic disease patients and the 
under-privileged group would likely be most 
affected.”3 
There can be different views and hence arguments 
about the aforementioned scenarios. Even given these 
scenarios to be probable, what financing arrangements 
should be implemented to address the presupposed 
challenges? That is, how financial resources in healthcare 
should best be pooled and distributed, in particular 
how providers should be paid? Unfortunately, these 
questions have not been fully deliberated, at least not at 
the community level.  
The public at large know little about the importance 
and implications of the various financing and payment 
arrangements to the cost, access and quality of 
healthcare services delivery. But they deserve to know. 
How resources are best pooled for healthcare and 
distributed is fundamentally an issue of societal and 
humanistic values. The current debate in healthcare 
reform elsewhere is increasingly torn between market 
orientation (based on economic considerations) and 
social responsibility. Hong Kong has traditionally 
exhibited a strong social responsibility for the health 
and healthcare of its residents. Free A&E services and 
nominal fees and charges in other services in the public 
healthcare sector were clear evidence. The formation of 
the Hospital Authority in 1991 was a sign of its further 
commitment towards that end.   
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That commitment, however, seems to have shifted when 
fees were levied for A&E services in public hospitals on 
29 November 2002. But what do Hong Kong residents 
prefer for their future public health system and what 
should policymakers do: more social responsibility, 
more market orientation, or a hybrid of the two?   
One of the aims of the Scheme is to enable more people 
to access private healthcare.4 While that obviously 
could facilitate movement from the public to the 
private sector, it is uncertain if in practice the reverse is 
also true. Will this then mean a move towards further 
market orientation? Not until we have clarity and public 
support of the long view of the type of public healthcare 
system that we want and should have, it could be 
counterproductive to introduce initiatives to move the 
system away from its stronghold of health as a right and 
social responsibility.    
Healthcare economics, financing and policy issues 
aside, it seems that most retirees, elderly, patients and 
families should prefer and want a health system free 
of avoidable and unnecessary worries or where they 
could have ease of access to quality healthcare with 
affordable and justifiable financial outlay and where 
healthcare costs will not wipe out most of their hard 
earned savings or assets or drive them to economically 
deprived conditions.  Will the Scheme help us move 
towards achieving a health system that we can feel safe, 
confident, secure and trusted?   
What will the Scheme likely do and 
not do? 
The objective of the scheme, as stated in the Chief 
Executive’s 2010-11 Policy Address, is “to provide the 
public with wider choices and better protection through 
government-regulated private health insurance and 
health care services.”5 This is to be achieved by:  
• encouraging the public to take-out health insurance 
and savings to enhance access to private healthcare 
services and to facilitate greater use of private 
services as an alternative to public services; and 
• increasing the transparency of service standards 
and price levels in the private health insurance 
and healthcare markets through the offering 
of packaged charging for common medical 
procedures. 
The benefits design of the Scheme is to provide cover 
for mainly hospitalisation and selected admission 
associated special ist  outpatient  consultations, 
investigations or procedures. Maternity services are 
not covered. To prevent abuse or overuse, the Scheme 
incorporates various utilisation management controls 
such as deductibles and co-payments that are common 
among private health insurance policies. On the other 
hand, how the Scheme will incentivise individual 
providers for improved performance and in helping 
patients stay healthy are visibly lacking.  
To ensure that the Scheme is attractive to the public 
to join and stay, especially those who already have 
private health insurance coverage, the Government 
will consider using the HK$50 billion earmarked for 
supporting healthcare reform to provide no-claim 
discounts of up to 30 percent for the public to join 
the scheme in the initial period and to offer premium 
rebates at age 65 or above based on the participant’s 
savings and length of continuously staying insured 
under the Scheme. 
It seems that the Scheme is designed primarily to lure 
patients away from using public hospital services, to 
incentivise them to stay insured and remain in the 
private sector. By enabling more people to use private 
healthcare on a sustained basis, it is anticipated that 
the Scheme will help public healthcare better focus 
on queue relief, being a safety net for all, serving the 
needy and providing acute and emergency care as well 
as catastrophic care. 
Very little, if any, is provided in the consultation 
document for how the Scheme may contribute to 
lowering healthcare costs,  enhancing equity of 
access and improving quality. In fact, there is limited 
evidence, based on international experience, that the 
Scheme, being a voluntary indemnity health insurance 
plan, will improve efficiency of the health system, 
reduce overall healthcare costs pressure, or relieve 
over-crowding in the public healthcare sector. 6 On the 
contrary, it will likely: 
• bring access inequity to plan benefits for consumers. 
• exacerbate healthcare cost increases. 
• stimulate demand or even abuse and overuse of 
healthcare services. 
• lead to adverse selection.
To mitigate the down-side risks, the Scheme will need, 
as proposed, extensive regulation, supervision and 
monitoring, including a strong supporting infrastructure 
and claims arbitration mechanism. These suggest 
that it will be an expensive system to implement and 
administer. 
Is the Scheme the right choice for 
Hong Kong? 
Hong Kong already has private health insurance in 
varying forms for decades. Around 3.5 million policies, 
comprising 2.0 million individual memberships and 
1.5 million group memberships, were in force in 2009. 
This represents 34 percent of the population having 
private health insurance and the number of individuals 
purchasing private health insurance has grown 
significantly in recent years.6 
The contribution of private health insurance to Hong 
Kong’s healthcare financing has stayed at 12 percent 
to 13 percent between 1998/90 and 2006/07. In terms 
of share of total expenditure on health, private health 
insurance grew at an average rate of nearly 9 percent 
per year during this period. In 2006/07, private hospitals 
incurred about a quarter of the expenditure on inpatient 
care, about half of which was financed by private health 
insurance. 
So, what is the point of introducing the proposed 
Scheme? 
The study commissioned by the Food and Health 
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Bureau on private health insurance outlined a number 
or inadequacies or challenges confronting insurers, 
consumers and providers in the existing private health 
insurance sector: 
For insurers:
• a n t i - s e l e c t i o n  a n d  n o n - d i s c l o s u r e  d u r i n g 
underwriting. 
• moral hazard and unnecessary admissions due to 
investigations. 
• limited private providers and limited application of 
clinical guidelines and audits. 
• non-transparent and rising medical fees. 
• private health insurance’s attractiveness dimmed by 
public services. 
For consumers:
• uncertainty of coverage and charges. 
• disputes over policy terms and conditions and their 
application. 
• non-transparent medical fees and lack of quality 
assurance. 
• non-portability of private health insurance.
For private hospitals and doctors:
• inadequate coverage. 
• coverage of outpatient procedures.
If the Scheme is to address the inadequacies of the 
current private health insurance market, then perhaps 
the ones worth the Government’s attention would be 
mainly those confronting consumers. Yet, these are 
issues that other health systems with private health 
insurance have long addressed successfully through 
regulation or policy changes.   
Does Hong Kong really need the force and weight of 
the huge designated HK$50 billion healthcare reform 
fund and the potentially high administrative cost of the 
proposed Scheme to institute such improvements in the 
private health insurance sector?
 
The cost benefit of the proposed Scheme is uncertain 
and appears unjustified. It is also not evident that 
the proposed Scheme can efficiently and effectively 
mobilise resources to help build an effective and 
sustainable healthcare system that ensures equitable 
access and provides adequate choice. If the objective is 
to put forward a voluntary supplementary healthcare 
financing scheme with wider choice and continuous 
protection, surely other viable options should be 
explored and presented for consultation. Unfortunately, 
this is not the case. 
Conclusion 
After two decades of consultation after consultation, 
Hong Kong deserves something more refreshing, 
precise, understandable and practical in revamping its 
healthcare system. We want a health system that gives 
us a brighter future about improving and sustaining our 
health and healthcare, not one that is suppressed by our 
own pessimism in its inevitable and insurmountable 
burdens or that which we strive to solve its problems by 
using the same kind of thinking that had created them. 
We cannot and should not allow prolonged malaise or 
more muddling through. Perhaps, a completely fresh 
and inclusive approach backed by renewed political 
determination to craft a clear new vision and innovative 
strategies to more efficiently mobilise existing and 
future resources is what is needed instead.  
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Dermatological Quiz
Dermatological Quiz
Dr. Lai-yin CHONG  
MBBS(HK), FRCP(Lond, Edin, Glasg), FHKCP, FHKAM(Med)
Private Dermatologist
Dr. Lai-yin CHONG  
This seven-year-old girl developed multiple pruritic,  discrete and 
monomorphous papules over both upper and lower limbs, and a few similar 
lesions over the trunk for one month. Apart from vague preceding flu-like 
symptoms, her past health was good. No other family members were involved. 
Questions:
1. What is your clinical diagnosis and differential diagnoses?
2. What are the possible related aetiological agents and which one is the   
    commonest nowadays?
3. How do you manage this condition?
Bilateral pruritic discrete papules at 
both forearms (See P. 33 for answers)
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Ms. Carman WONG
Tel: 2527 8285
1:00pm
2:00pm
HKMA Kowloon West Community Network - Erectile Disorder” (PENDING)
Organiser: HKMA Kowloon West Community Network, Chairman: TBC, Speaker: TBC, 
Venue: Crystal Room I-III, 30/F., Panda Hotel, Tsuen Wan, N.T.  
Ms. Viviane LAM
Tel: 2527 8452
1 CME Point
HKMA Structured CME Programme with Hong Kong Sanatorium & Hospital Year 
2010 – Diagnosis of head and neck cancer: “look, feel and what else?”
Organiser: The Hong Kong Medical Association, Speaker: Prof. William I. WEI, Venue: 
The HKMA Dr. Li Shu Pui Professional Education Centre, 2/F, Chinese Club Building, 
21-22 Connaught Road Central, Hong Kong
THU9
Dr. Hing-hoi HUNG / 
Ms. Tammy HUNG
Tel: 2958 6006 / 9609 6064
Fax: 2958 6076 / 8344 5115, 
CME Accreditation: 1 Point (The 
College of Surgeons of Hong Kong)
A “Hard” Scrotal Abscess 
Organiser: Hong Kong Urological Association, Chairman: Dr. Yin-chak LAW, Speaker: 
Dr. Ringo Wing-hong CHU, Venue: Seminar Room, G/F, Block A, Queen Elizabeth 
Hospital, Kowloon 
Ms. Jo WONG
Tel: 2527 8285
HKMA Choir Voice Training Course 2010
Organiser: The Hong Kong Medical Association, Venue: GP1, HKCC
MON6
Dr. Gilberto LEUNG
Tel: 2255 3368   Fax: 2818 4350
Hong Kong Neurosurgical Society Monthly Academic Meeting – Brain Edema
Organiser: Hong Kong Neurosurgical Society, Chairman: Dr. KY Chan, Speaker: Dr. Peter 
WOO, Venue: Seminar Room, Ground Floor, Block A, Queen Elizabeth Hosptial
Ms. Alice TANG
Tel: 2527 8285
1 CME Point
HKMA Central, Western & Southern Community Network  Certificate Course on 
Orthopaedics (V) 
Organiser: HKMA Central, Western & Southern Community Network, Chairman: Dr. YIK 
Ping Yin, Speaker: Dr. KONG Kam Fu, James, Venue: The HKMA Dr. Li Shu Pui 
Professional Education Centre, 2/F, Chinese Club Building, 21-22 Connaught Road 
Central, Hong Kong
WED8
Department of Surgery, Hong 
Kong Sanatorium & Hospital
Tel: 2835 8698    Fax: 2892 7511
1 CME Point
Joint Surgical Symposium – Recurrences and Prognostication for Esophageal and 
Gastric Cancer
Organiser: Department of Surgery The University of Hong Kong Sanatorium & Hospital, 
Speaker: Professor Simon LAW, Professor CHU Kent-Man, Chairman: Prof. Law Wai Lun, 
Venue: Hong Kong Sanatorium & Hospital
Mr. Patrick TSANG
Tel: 3971 2940
HKMA Kowloon City & Kowloon East Community Networks - From Evidence to Action 
- Achieving Target Lipid Goal to Reduce Cardiovascular Risk
Organiser: HKMA Kowloon City & Kowloon East Community Networks, Speaker: Dr. 
AU YEONG Chi Keung, Chairman: TBC, Venue: Spotlight Recreation Club (博藝會)4/F., 
Screen World, Site 8, Whampoa Garden, Hunghom, Kowloon
FRI3
8:00am – 9:00am
Ms. Viviane LAM
Tel: 2527 8452
1 CME Point
HKMA CME Series on Chronic Hepatitis B and its Complications (Hong Kong Island 
Series)
Organiser: The Hong Kong Medical Association, Speaker: Dr. CHAN Lik Yuen, Henry, 
Chairman: Dr. LEE Fook Kay, Aaron, Venue: The HKMA Dr. Li Shu Pui Professional 
Education Centre, 2/F, Chinese Club Building, 21-22 Connaught Road Central, Hong Kong
THU2
WED
Mr. Patrick TSANG
Tel: 3971 2940
1 CME Point1
HKMA HK East Community Network – New Treatments in LDL and HDL for CV Risk 
Reduction
Organiser: HKMA HK East Community Network, Speaker: Dr. TSE Tak Sun, Chairman: 
Dr. YIP Yuk Pang, Kenneth, Venue: Hoi Yat Heen, Harbour Plaza North Point, 665 
King’s Road, North Point, Hong Kong(香港北角英皇道665號北角海逸酒店海逸軒)
Date  / Time Function Enquiry / Remarks
1:00 pm 
12:30pm
1:00pm
Ms. Viviane LAM
Tel: 2527 8452
2 CME Point
2:30pm
6:30pm
11 Refresher Course for Health Care Providers 2010/2011Organiser: The Hong Kong Medical Association, Speaker: Dr. MAK Kan Hing, Venue: OLMH
Asian Dermatological Association  - 33rd Council Meeting & 23rd AGM
Organiser: Asian Dermatological Association, Venue: Mandarin Oriental, Sanya, China
SAT
Ms. Viviane LAM
3 CME Point
2:00pm HKMA Certificate Course on Family Medicine 2010
Organiser: The Hong Kong Medical Association, Speaker: Dr. YUEN Chung Lau, 
Natalis; Dr. SEE Chung Pak, Venue: QEH
Ms. Peony CHAN
Tel: 2527 8285
Miss. Peony CHAN
Tel: 2527 8285
2:00pm
8:00pm
HKMAPS 4th photo competition & sharing session
Organiser: The Hong Kong Medical Association, Venue: HKMA Head Oﬃce (5/F., Duke 
of Windsor Social Service Building, 15 Hennessy Road, Hong Kong)
7:30pm
9:00am
HKMA Tennis Tournament
Organiser: The Hong Kong Medical Association, Venue: Kowloon Tong Club
Seminar on Doping Control in Sports
Organiser: The Federation of Medical Societies of Hong Kong, Sports Federation & 
Olympic Committee of Hong Kong, China and Hong Kong Anti-Doping Committee, 
Venue: Olympic House, 1 Stadium Path, So Kon Po, Causeway Bay, Hong KongSUN5
Ms. Kandy WAN
Tel: 2811 9711
1.5 CME Point
1:00pm
8:00pm
HKMA HK East Community Network – 2010 RA Classification Criteria: Importance of 
Early Diagnosis and Effective Treatment
Organiser: HKMA HK East Community Network, Chairman: Dr. NGAN Sze Yuen, 
Silas, Speaker: Dr. CHAN Tak Hin, Venue: Sportful Garden Restaurant (陶源酒家)1/F. & 
2/F., Tai Tung Building, 8 Fleming Road, Wanchai, Hong Kong
Ms. Christine WONG
Tel: 2527 8285
8:00pm
7:30am
1:00pm
HKMA Council Meeting
Organiser: The Hong Kong Medical Association, Chairman: Dr. K Choi, Venue: HKMA 
Head Oﬃce (5/F., Duke of Windsor Social Service Building, 15 Hennessy Road, Hong 
Kong)
Ms. Sonia Cheung
Tel: 2527 8898  Fax: 2865 0345
Ms. Sonia Cheung
Tel: 2527 8898  Fax: 2865 0345
Ms. Sonia Cheung
Tel: 2527 8898  Fax: 2865 0345
FMSHK Officers’ Meeting
Organiser: The Federation of Medical Societies of Hong Kong, Venue: Gallop, 2/F., Hong  
Kong Jockey Club Clubhouse, Shan Kwong Road, Happy Valley, Hong Kong
TUE7
1:00 pm 
7:30pm
Ms. Alice TANG; Miss Carman 
WONG
Tel: 2527 8285
HKMA - Diagnosing and Assessing Lung Diseases in the Office (YTM Series)
Organiser: Hong Kong Medical Association, Hong Kong Thoracic Society, American 
College of Chest Physicians (Hong Kong and Macau Chapter), Hong Kong Society of 
Paediatric Respiratory and the Hong Kong Asthma Societ, Chairman: TBC, Speaker: 
TBC, Venue: Kwong Wah Hospital (PENDING)
Ms. Peony CHAN
Tel: 2527 8285
HKMA Tennis Tournament 
Organizer: The Hong Kong Medical Association, Venue: Kowloon Tong Club
12 SUN
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Calendar of Events
1:00 pm 
8:00 pm 
Ms. Alice TANG
Tel: 2527 8285
 
HKMA New Territories West Community Network – Infant Nutrition (PENDING)
Organiser: HKMA New Territories West Community Network, Chairman: Dr. TSUI 
Fung, Speaker: TBC, Venue: Plentiful Delight Banquet (元朗喜尚嘉喜酒家), 1/F., Ho 
Shun Tai Building, 10 Sai Ching Street, Yuen Long, N.T.
FMSHK Executive Committee Meeting
Organiser: The Federation of Medical Societies of Hong Kong, Venue: Council Chamber, 
4/F, Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, Hong Kong
16 THU
1:00 pm Mr. Taky IP
Tel: 6397 7411
HKMA Hong Kong East Community Network – The Role of TZDs in the Management 
of Type 2 Diabetes
Organiser: HKMA Hong Kong East Community Network, Chairman: Dr. YOUNG Ying 
Nam, Dominic, Speaker: Dr. WONG Bun Lap, Bernard, Venue: 迎囍大酒樓杏花村盛泰道
100號杏花新城203號舖
14 TUE
Ms. Winniea LEE
Tel: 2861 0220
HKMA Kowloon East Community Network – Joint CME Course for Health Personnel 
2010 on "Type 2 DM and Insulin Management"
Organiser: HKMA Kowloon East Community Network; Hong Kong College of Family 
Physicans; United Christian Hospital, Chairman: Dr. MA Ping Kwan, Danny, Speaker: 
Dr. TSANG Man Wo, Venue: Crystal Ball Room, 2/F., Cityview Hotel (formerly YMCA 
International House), 23 Waterloo Road, Kowloon (Yau Ma Tei MTR Exit A2)
18 SAT
1:30pm
Ms. Jo WONG
Tel: 2527 8285
HKMA 90th Anniversary Ball
Organiser: The Hong Kong Medical Association, Venue: Grand Ballroom, Conrad Hong 
Kong
FMSHK 45th Anniversary Annual Dinner - Sensational 45th Anniversary with Music of 
the Eras
Organiser: The Federation of Medical Societies of Hong Kong
Venue: Run Run Shaw Hall, The Hong Kong Academy of Medicine Jockey Club 
31 FRI
8:00pm
8:30pm
Ms. Peony CHAN
Tel: 2527 8285
HKMA 90th Anniversary Ball
Organizer: The Hong Kong Medical Association, Venue: Kowloon Tong Club19 SUN
FRI
Ms. Candy LAW
Tel: 6509 6582  Fax: 3528 5727, 
Email: candy@hksoqol.org, 
Website: 
http://ww.hksoqol.org/conf2010
17 2010 Asian Chinese Quality of Life ConferenceOrganiser: International Society for Quality of Life Research – Asian Chinese Chapter; Family Medicine Unit, Department of Medicine, Li Ka Shing Faculty of Medicine, The 
University of Hong Kong & Hong Kong Society for Quality of Life, Co-Chairmen: Prof. 
Feng-bin LIU, Prof; Cindy LAM & Mr. Kwok-fai LEUNG, Speakers: Various, Venue: Li 
Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, 
Pokfulam, Hong Kong
Date  / Time Function Enquiry / Remarks
7:30pm
Courses / Meetings
Seminar on Wound Care – Integrative Perspectives from Western and Chinese Medicine
Organiser: Association for Integrative Aesthetic Medicine, Hong Kong (AIAM), Chairman: Dr YU Chau Leung, Speaker: Dr. CHIU 
Kai Ming, Leo, Dr S.K. HUI & CMP FU Wen Shu, Venue: Lecture Hall, 4/F Duke of Windsor Social Service Building, 15 Hennessy 
Road, Wanchai, Hong Kong, Tel: 3575 8600, Fax: 2301 2414, Email: aiam.hk@yahooo.com, CME Accreditation: pending 
Hong Kong International Acupuncture Conference – Neurological and Mental Illness 
Organiser: Hong Kong Association for Integration of Chinese-Western Medicine & Hospital Authority, Chairman: Dr. Vivian 
Taam Chi Woon WONG, Speakers: Various, Venue: Hong Kong Academy of Medicine Jockey Club Building, Enquiry: Ms. 
Jessie CHOW & Ms. Y.C. YEUNG, Tel: 2871 8787, 2871 8897 / 3119 1850, Fax: 2871 8898
Hepatobiliary & Pancreatic Surgery and Liver Transplantation 
Organiser: Department of Surgery, The University of Hong Kong, Queen Mary Hospital & Hong Kong Chapter of American 
College of Surgeons, Venue: Underground Lecture Theatre, New Clinical Building, Queen Mary Hospital, Pokfulam, Hong 
Kong, Enquiry: Forum Secretary, Hong Kong Surgical Forum, Tel: (852) 2255 4885 / (852) 2255 4886, Fax: (852) 2819 3416, E-mail: 
hksf@hku.hk, Web-site: http://www3.hku.hk/surgery/forum.php
18th Asian Congress of Surgery & 37th Philippine College of Surgeons Mid-year Convention
Organiser: Asian Surgical Association, Venue: Waterfront Cebu City Hotel & Casino, Lahug, Cebu City, Philippines, Enquiry: 
Congress Secretariat, Tel: (632) 9274973-74; (632) 9281083; (632) 9292359, Fax: (632) 9292297, E-mail: secretariat@acs2011.org, 
Website:  www.acs2011.org
12/1/2011
14-16/1/2011
22/1/2011
12-14/5/2011
(18,19)
Ms. Alice TANG
Tel: 2527 8285
HKMA Central, Western & Southern Community Network - Updates on Diabetes 
Management
Organiser: HKMA Central, Western & Southern Community Network, Chairman: TBC, 
Speaker: Dr. TONG Chun Yip, Peter, Venue: The HKMA Dr. Li Shu Pui Professional 
Education Centre, 2/F, Chinese Club Building, 21-22 Connaught Road Central, Hong Kong
1:00pm
Ms. Sonia Cheung
Tel: 2527 8898  Fax: 2865 0345
Ms. Sonia Cheung
Tel: 2527 8898  Fax: 2865 0345
HKDA 57th Annual Ball
Organiser: Hong Kong Dental Association, Venue: Hong Kong Convention & Exhibition 
Centre
Ms. Glenda Wong
Tel: 2528 5327
News from Member Societies
1. Osteoporosis Society of Hong Kong
Updated office-bearers for the year 2010-2012 are as follows: President: Dr. Tai-pang IP; Honorary Secretary: Dr. 
Ka-kui LEE; Honorary Treasurer: Dr. Eddie Siu-lun CHOW
The FMSHK would like to send its congratulations to the new office-bearers and look forward to working 
together with the society. 
Society News
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Dermatological Quiz
Answer to Dermatological Quiz
1.
2.
3.
Papular acrodermatitis (Gianotti-Crosti syndrome). The 
main differential diagnoses are scabies, arthropod bite, 
papular urticaria, drug eruption, molluscum contagiosum 
and other viral exanthema. 
Hepatitis B virus was originally quoted as its aetiological 
agent, but is actually an uncommon link. Epstein-Barr 
virus is now the commonest reported cause.  Other agents 
reported include cytomegalovirus, coxsackie viruses B, 
respiratory syncytial virus, parainfluenza, poliovirus and 
beta-haemolytic streptococcus. Post-immunisation with 
vaccinia or BCG has also been reported as related cause.
As the natural course of this condition is benign, the 
treatment is mainly supportive. A thorough history 
and physical examination should be performed, but 
evaluation for hepatitis or other specific viral agents (e.g. 
hepatitis B virus) should be performed only if indicated. 
Although this condition mainly occurs in children, it has 
been reported in adults as well, but exclusively in women. 
The prognosis is good with spontaneous resolution, 
usually within 3-4 weeks, although the eruption may 
occasionally persist for up to several months. If lesions 
persist, other diagnosis should be considered.
Dr. Lai-yin CHONG
  
MBBS(HK), FRCP(Lond, Edin, Glasg), FHKCP, FHKAM(Med)
Private Dermatologist
 The Federation of Medical Societies of Hong Kong
 4/F Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, HK
 Tel: 2527 8898           Fax: 2865 0345
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